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Heart rate variabilityBackground: The circadian autonomic ﬂuctuation in chronic kidney disease (CKD) patients has not yet been fully
elucidated. The aim of this study was to compare the autonomic ﬂuctuation using heart rate variability between
patients with and without CKD.
Methods: The study population consisted of consecutive 101 non-diabetic CKD patients (Stages 3–5, 54 males,
70± 10 years) and 129 age- and sex-matched controls without CKD (65 males, 68± 10 years) who underwent
24-hour Holter monitoring. The proportion of successive normal sinus NN intervals that differ N50 ms (pNN50)
and the high-frequency component (HF) were adopted as vagal parameters. The low- to high-frequency ratio
(LF/HF ratio) was evaluated as a sympatho-vagal balance parameter. To evaluate the direct contribution of
CKD and other comorbidities to the autonomic variation, the regression analysis was performed after we arbi-
trarily divided 24 h into night-time (10 PM–8 AM) and day-time (8 AM–10 PM).
Results: The CKD patients had higher prevalence of hypertension, hyperuricemia, and low hemoglobin as com-
pared to controls (P b 0.05). Both groups showed surges of pNN50 and HF nocturnally. However, these nocturnal
surgeswere signiﬁcantly suppressed in CKD (P b 0.05), reﬂecting the impaired vagal activity. Regression analysis
demonstrated an independent relation between the nocturnal reduction of vagal parameters and CKD (P b 0.05),
and also revealed that the LF/HF ratio was not related to CKD (P N 0.05), but to low Hb (P b 0.05).
Conclusion: The circadian autonomic, particularly vagal, ﬂuctuationswere impaired in non-diabetic CKD patients
independently from aging and comorbidities. Further research is required to assess the association between this
impairment and prognosis of CKD patients.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic kidney disease (CKD) has been associated with disturbed
autonomic control that is linked to an increased risk of sudden cardiac
death (SCD) [1,2,3]. Moreover, the incidence of cardiac events or
death is reported more frequently in the morning in patients with
CKD [4]. This circadian variation of cardiac events and death may be re-
lated to the autonomic circadian variation. In addition, dialysis patients
have been reported to have a higher prevalence of abnormal heart rate
variability (HRV) [5].arMedicine, University of Tokyo
kimoto).
d Ltd. This is an open access article uIn the last two decades, autonomic evaluation through HRV, consid-
ered to reﬂect autonomic activation, has been conducted in patients un-
dergoing hemodialysis, demonstrating that a decreased HRV was
associated with higher mortality, even after adjusting for the presence
of diabetes mellitus (DM) [6]. Renal failure and hemodialysis patients
showed decreased HRV [7], independent of diabetic neuropathy. More-
over, regular hemodialysis itself can directly affect HRV [8], therefore
circadian HRV in CKD patients not undergoing hemodialysis may differ
from that of CKD patients on hemodialysis. However, the exact relation-
ship between non-diabetic CKD, end-stage renal failure, and HRV re-
mains to be clariﬁed, even though autonomic disturbances in patients
on hemodialysis have already been reported.
In this study, we aimed at 1) evaluating the circadian variation of
cardiac autonomic function in non-diabetic CKD patients by analysis of
24-hour Holter electrocardiograms (ECG); 2) comparing the cardiacnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline patient characteristics.
CKD (+)
N = 101
CKD (−)
N = 129
P value
Male 54 (53%) 65 (50%) 0.64
Age (years) 70.1 ± 10.0 68.1 ± 10.4 0.14
Estimated GFR (mL/min/1.73 m2) 39.2 ± 16.0 75.6 ± 9.7 b0.001
On hemodialysis 5 (5%) 0 (0%) 0.011
Height (cm) 160.2 ± 9.1 160.2 ± 9.5 0.98
Body weight (kg) 56.5 ± 12.5 57.4 ± 13.2 0.65
Body mass index 21.9 ± 3.6 22.2 ± 3.7 0.51
Mean heart rate (bpm) 70.6 ± 10.3 71.6 ± 9.7 0.40
Hypertension 61 (60%) 54 (42%) 0.0053
Systolic blood pressure (mm Hg) 126 ± 19 128 ± 17 0.58
Diastolic blood pressure (mm Hg) 70 ± 12 75 ± 11 0.002
Hyperuricemia 32 (32%) 3 (2%) b0.001
Dyslipidemia 40 (40%) 42 (33%) 0.27
Ischemic heart disease 10 (10%) 12 (9%) 0.88
Hb (g/dL) 12.3 ± 2.2 13.6 ± 1.5 b0.001
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3) evaluating the direct relationship between the presence of CKD and
autonomic disturbance using multivariate regression analysis.2. Methods
2.1. Study population
The study population consisted of patients who underwent 24-hour
Holter ECGs between 2009 and 2011, with an estimated glomerular ﬁl-
tration rate (eGFR) b60 mL/min/1.73 m2 [9].
These patients were compared against an age- and sex-matched con-
trol group who were randomly selected from patients who underwent
24-hour Holter ECGs between January 2010 and June 2010, and who
had eGFR ≥60 mL/min/1.73 m2.
Patients with over 2000 presystolic atrial or ventricular complex
(PAC or PVC, respectively) beats per day, or with over 3000 PAC and
PVC per day in total were excluded. Other exclusion criteria included
type 1 or 2 DM, congenital heart disease, atrial ﬁbrillation, signiﬁcant
heart valve disease, hospital admission due to congestive heart failure
within 6 months, and β-blocker use.2.2. Clinical data
Baseline clinical information was collected retrospectively based on
clinical records. Ambulant blood pressure and hemoglobin (Hb)was re-
corded. eGFR was determined based on the new Japanese coefﬁcient-
modiﬁed Modiﬁcation of Diet in Renal Disease (MDRD) study equation
[10]. The presence of ischemic heart disease was deﬁned as a history of
over 75% stenosis in a coronary artery diagnosed on coronary angiogra-
phy or coronary CT.Table 2
Echocardiographic characteristics.
CKD (+)
N = 101
CKD (−)
N = 129
P value
LVEDD (mm) 45.9 ± 6.0 44.6 ± 4.7 0.10
LVEDS (mm) 28.0 ± 5.7 26.7 ± 4.2 0.077
SWT (mm) 10.3 ± 2.0 9.2 ± 1.8 b0.001
PWT (mm) 9.8 ± 1.8 9.1 ± 1.3 0.006
Left ventricular mass (g) 161 ± 47 138 ± 43 b0.001
Ejection fraction (%) 68.8 ± 10.0 70.3 ± 8.3 0.27
Left atrial diameter (mm) 38.3 ± 7.4 36.3 ± 6.2 0.0512.3. Echocardiography
In all patients and controls, cardiac chamber quantiﬁcation by 2D
echocardiography was performed according to guidelines provided by
the American Society of Echocardiography [11]. Left ventricular end-
diastolic dimension (LVEDD), left ventricular end-systolic dimension
(LVEDS), diastolic posterior left ventricular wall thickness (PWT), dia-
stolic interventricular septum thickness (SWT), LV ejection fraction
(LVEF), and LV mass were assessed. The LV mass was calculated as
follows: LV mass (g) = 0.8 × [1.04 × {(LVEDD + PWT + SWT)3 −
(LVEDD)3}] + 0.6.2.4. Holter ECG analysis
Holter ECG was retrospectively analyzed by a medical technologist
blinded to patient information, and resultswere conﬁrmed by a cardiol-
ogist. The analysis was performed using the SCM-8000 system (Fukuda
Denshi, Tokyo, Japan).
The following indices were analyzed every hour over a 24 h period.
Time domain analysis: heart rate (HR), standard deviation of the NN
interval (SDNN), proportion of NN50 (the number of pairs of successive
NNs that differ by N50 ms divided by the total number of NNs; pNN50).
Frequency domain analysis: low-frequency component (LF; 0.03–
0.15 Hz), high-frequency component (HF; 0.15–0.4 Hz), LF/HF ratio.
To evaluate the circadian ﬂuctuation of cardiac autonomic function,
the 24 h period was arbitrary divided into day-time (8–22 o'clock)
and night-time (22–8 o'clock).
2.5. Statistical analysis
The chi-square test, Student t test, or 1-way analysis of variance was
performed when appropriate. If the response variables were not nor-
mally distributed, a logarithmic transformation of the outcome variable
was used to obtain normal distribution. Continuous data were shown as
mean ± SD for normally distributed data, and as median values [ﬁrst
quartile–third quartile] otherwise. A signiﬁcance level of 5% was used
for global test statistics.
All authors had full access to the data, and have read and agreed to
the manuscript as written. The study was approved by the Tokyo Uni-
versity Hospital Institutional Review Board.
3. Results
3.1. Patient characteristics
101 CKD patients and 129 controls were enrolled in this study. Base-
line patient characteristics are shown in Table 1. The number of patients
with Stages 3, 4, and 5 CKD were 76, 10, and 15, respectively
Although the prevalence of hypertension was signiﬁcantly higher in
CKD patients, the ambulant diastolic blood pressure was signiﬁcantly
lower (P = 0.0020). CKD patients had lower Hb (P b 0.001).
There were no signiﬁcant differences in LV dimensions, LVEF, and
left atrial diameter (Table 2), however the LV wall was signiﬁcantly
thicker and LV mass was larger in CKD patients.
3.2. Time domain analysis
Although there were no signiﬁcant differences in the average HR
over a 24-hour period between the two groups (70.6 ± 10.3 bpm in
CKDpatients vs 71.6±9.7 bpm in controls, P=0.40), theHR in CKDpa-
tients was signiﬁcantly lower compared to controls during the day-time
periods on hourly analysis (Fig. 1a).
The SDNN over a 24-hour period of CKD patients was signiﬁcant-
ly lower compared to controls (115.3 ± 39.1 ms vs 131.5 ± 31.8 ms,
P b 0.001). On hourly analysis, SDNN of CKD patients was signiﬁcantly
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early morning (5–9 o'clock) (Fig. 1b).
The pNN50 over a 24-hour period of CKD patients trended lower
compared to controls (2.1 [0.5–4.9] vs 2.8 [0.9–6.1], P = 0.064), and
was signiﬁcantly lower compared to controls throughout the night-
time period (22–6 o'clock) on hourly analysis (Fig. 1c).
These results suggest that vagal activation during night-time and
the early morning period in CKD patients was lower compared to
controls.Fig. 1. Time trends of time domain parameters over 24 h. a: The heart rate in patients with CKD
niﬁcant differences. b: The SDNN in patients with CKDwas signiﬁcantly lower at the beginning
the early morning. c: The pNN50 in patients with CKD was signiﬁcantly diminished during nig
disease.3.3. Frequency domain analysis
HF and LF over a 24-hour period of CKD patients were signiﬁcantly
lower compared to controls (112.5 [54.1–166.0] vs 159.0 [95.5–268.9],
P b 0.001, 174.4 [85.6–260.6] vs 233.2 [155.6–441.6], P b 0.001,
respectively).
HF demonstrated signiﬁcant differences between the evening and
early morning periods on hourly analysis (Fig. 2a). The difference be-
tween the two groups became larger particularly during midnight.was signiﬁcantly lower during day-time. The heart rate during night-time showed no sig-
of sleep and in the earlymorning. The deviation between the two groupswas the largest in
ht-time. †: P b 0.05 between patients with CKD and without CKD. CKD = chronic kidney
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throughout a 24-hour period (Fig. 2b).
The LF/HF ratio over a 24-hour period of CKD patients trended
lower compared to controls (1.6 [0.8–2.4] vs 1.8 [1.1–2.7], P =
0.076).
On hourly analysis, the LF/HF ratio in CKD patients was signiﬁcantly
lower compared to controls during day-time (Fig. 2c). Interestingly, the
LF/HF ratio showed no signiﬁcant differences during night-time except
at 2 o'clock.
This data suggests that vagal activation in CKD patients was lower
compared to controls, and the sympatho-vagal balance differenceFig. 2. Time trends of frequency domain parameters over 24 h. a: The HF in patients with CKDw
2 groups was the largest during night-time. b: The LF in patients with CKD was signiﬁcantly dim
day-time. †: P b 0.05 between patients with CKD and without CKD. CKD = chronic kidney disebetween day-time and night-time periods in CKD patients was
smaller compared to controls.3.4. Circadian ﬂuctuation
pNN50 during day-time was signiﬁcantly associated with the pres-
ence of hypertension after adjusting for age (Table 3). CKD was not a
signiﬁcant index of pNN50 during day-time. However, pNN50 during
night-time was signiﬁcantly and independently associated with male
sex and CKD.as signiﬁcantly diminished almost throughoutmost of the 24 h. The deviation between the
inished over 24 h. c: The LF/HF ratio in patients with CKD was signiﬁcantly lower during
ase.
Table 4
Association between clinical characteristics and HF.
Day-time Night-time
Hazard ratio
[95% CI]
P value
Hazard ratio
[95% CI]
P value
Hypertension 0.85 [0.74–0.98] 0.024 0.93 [0.80–1.07] 0.32
Chronic kidney disease 0.86 [0.74–1.00] 0.057 0.81 [0.69–0.95] 0.0086
Male 0.89 [0.76–1.05] 0.16 0.88 [0.74–1.03] 0.12
Age (10 years) 1.06 [0.93–1.21] 0.37 0.95 [0.83–1.09] 0.48
Left ventricular mass
(10 g)
1.01 [0.98–1.05] 0.38 0.99 [0.96–1.02] 0.58
Hyperuricemia 1.07 [0.88–1.30] 0.51 1.11 [0.90–1.37] 0.31
Dyslipidemia 0.95 [0.82–1.10] 0.52 0.97 [0.83–1.13] 0.66
Hemoglobin (1 g/dL) 0.99 [0.91–1.07] 0.77 1.04 [0.96–1.13] 0.37
Ischemic heart disease 0.99 [0.80–1.23] 0.92 0.99 [0.79–1.25] 0.96
Bold values indicate level of signiﬁcance = 5%
Table 3
Association between clinical characteristics and pNN50.
Day-time Night-time
Hazard ratio
[95% CI]
P value Hazard ratio
[95% CI]
P value
Hypertension 0.69 [0.53–0.88] 0.0036 0.81 [0.64–1.03] 0.083
Male 0.77 [0.58–1.03] 0.08 0.73 [0.56–0.97] 0.027
Age (10 years) 1.24 [0.97–1.58] 0.084 1.06 [0.84–1.33] 0.62
Hyperuricemia 1.29 [0.90–1.86] 0.17 1.35 [0.96–1.91] 0.088
Chronic kidney disease 0.88 [0.67–1.16] 0.37 0.73 [0.56–0.95] 0.02
Left ventricular mass
(10 g)
1.02 [0.96–1.09] 0.45 1.01 [0.95–1.06] 0.85
Ischemic heart disease 0.87 [0.58–1.29] 0.48 0.83 [0.57–1.21] 0.33
Dyslipidemia 1.08 [0.82–1.41] 0.59 1.09 [0.84–1.41] 0.5
Hemoglobin (1 g/dL) 1.00 [0.86–1.16] 0.99 1.12 [0.97–1.28] 0.12
Bold values indicate level of signiﬁcance = 5%
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niﬁcantly associated with reduced HF during night-time after adjusting
for age and Hb (Table 4).
The LF/HF ratio did not show a signiﬁcant relationship with CKD
after adjusting for age, Hb, and sex (Table 5). Anemia and older age
were signiﬁcantly associated with a lower LF/HF ratio.
These results from regression analysis suggest that CKD indepen-
dently affected vagal activation, particularly during night-time, howev-
er, did not affect the sympatho-vagal balance.
4. Discussion
Themajor ﬁndings of our study are the following: 1.) HRV parameters
of non-diabetic CKD patients, which were related to cardiac vagal func-
tion, were signiﬁcantly lower during night-time compared to those with-
out CKD; 2.) non-diabetic CKDwas an independent factor for reduction of
cardiac vagal function, particularly during night-time; and 3.) sympatho-
vagal balance was not affected by CKD, but by anemia.
To the best of our knowledge, this is the ﬁrst detailed report investi-
gating the direct relationship between circadian cardiac vagal activity
and non-diabetic renal dysfunction, and the abnormal circadian ﬂuctu-
ation of cardiac vagal activation in non-diabetic CKD patients.
4.1. Cardiac autonomic disturbance in CKD patients
Sympathetic overactivity in CKD patients has been previously dem-
onstrated by measuring sympathetic-nerve discharge [3] and by an in-
crease in catecholamine concentration [12].
The LF/HF ratio has been utilized to evaluate cardiac sympatho-vagal
balance through HRV, although it remains debatable if it could be used
as a marker of cardiac sympathetic activity [13]. In our study, CKD pa-
tients showed a signiﬁcantly lower HR and LF/HF ratio during day-
time (Figs. 1a, 2c). A higher HR in individuals without CKDmay be sec-
ondary to a more active day-time period, leading to a higher LF/HF ratio
reﬂecting higher sympathetic activity. In fact, the LF/HF ratio was not
signiﬁcantly associated with CKD after adjusting for HR.
There were no signiﬁcant differences in night-time HR between the
2 groups. Although the prevalence of hypertension was higher in CKD
patients, the blood pressure itself was well controlled with medical
therapy, and left ventricular functionwaswell preserved. This could ex-
plain the night-time HR data. We have to emphasize that there were
signiﬁcant discrepancies in vagal parameters during night-time despite
similar HR between the two groups.
In our study, not onlywere the vagal parameters in CKDpatients sig-
niﬁcantly lower, but LF was also signiﬁcantly diminished throughout
24 h. Although Vita et al. also showed that LF in hemodialysis patients
was signiﬁcantly reduced, no signiﬁcant differences in HF and the LF/
HF ratio were demonstrated [14]. This discrepancy could be attributed
to differences in the patient population.
The presence of hypertension, obesity or diabetes mellitus, aging,
and the LVmass has been reported to affect theHRV [15]. The regression
analysis incorporating these indices showed that the vagal disturbance
was independently associated with the presence of CKD.
These comorbidities and factors showed no signiﬁcant association
with HRV in our study. This can be attributed to optimal control with
medical therapy of the included patients, as shown in Tables 1 and 2.
The mechanism of vagal disturbance in patients with CKD has not
yet been clariﬁed. The data in the present study may reﬂect a higher
sympathetic activity, which subsequently suppressed the vagal activity
as the result of interaction.
4.2. Circadian ﬂuctuation of HRV in CKD patients
Circadiandisturbance of HRVhas been reported in patientswithDM,
obstructive sleep apnea, and ischemic heart disease [16,17]. In our
study, vagal surge during night-time was diminished in CKD patientsand corresponded to the report from Roumelioti et al. [18], which in-
cluded more severe CKD and diabetic patients.
Abnormal circadian ﬂuctuation in CKD patients could affect the oc-
currence of SCD [4]. Lack of vagal surge during night-time and in the
early morningmay explain a higher SCD occurrence during these times.
CKD patients had thicker LV walls, which might reﬂect pressure
overload. A previous report demonstrated that cardiac ﬁlling pressure
affected sympathetic activity through norepinephrine spillover [19].
CKD patients could have higher ﬁlling pressures, resulting in lower
vagal activation.
The LF/HF ratio, whichwas considered to partially reﬂect sympatho-
vagal balance, was not associated with CKD (Table 5). We incorporated
Hb as a parameter and showed that lower Hb conditions resulted in
lower LF/HF, which corresponds to previous reports of anemia-
associated reduction of HRV [20].
Normally, lower LF/HF reﬂects lower sympathetic activity or higher
vagal activity. However, as previously reported, remarkable HRV reduc-
tion, including LF/HF, was demonstrated in CKD patients. Moreover,
lower LF/HF was reported to be associated with poorer prognosis [1,
21]. Our data suggests that this LF/HF reduction was associated not
with CKD but with anemia. In fact, Furuland et al. demonstrated that
Hb normalization improved HRV in CKD patients [22].
In addition, apparent day-time LF/HF reduction in our study was
considered to be due to signiﬁcantly low LF. LF is known to be affected
not only by sympathetic activation, but also by parasympathetic activa-
tion [23]. The detailed mechanism of LF/HF modulation in CKD patients
should be further investigated.
4.3. Clinical implications
A recent study demonstrated that primary prevention of SCD utiliz-
ing implantable cardioverter-deﬁbrillators can improve the prognosis of
Table 5
Association between clinical characteristics and LF/HF ratio.
Day-time Night-time
Hazard ratio
[95% CI]
P value Hazard ratio
[95% CI]
P value
Age (10 years) 0.83 [0.75–0.91] b0.001 0.90 [0.81–0.99] 0.024
Hemoglobin (1 g/dL) 1.08 [1.02–1.15] 0.0053 1.07 [1.01–1.14] 0.016
Male 1.11 [1.00–1.24] 0.057 1.19 [1.06–1.33] 0.0028
Chronic kidney disease 0.93 [0.84–1.04] 0.19 0.98 [0.87–1.09] 0.65
Left ventricular mass
(10 g)
0.99 [0.97–1.01] 0.37 1.00 [0.98–1.03] 0.79
Hyperuricemia 0.97 [0.84–1.11] 0.62 0.94 [0.82–1.09] 0.42
Dyslipidemia 0.99 [0.89–1.09] 0.78 0.96 [0.86–1.06] 0.39
Ischemic heart disease 0.99 [0.85–1.15] 0.86 0.91 [0.78–1.07] 0.26
Hypertension 0.99 [0.90–1.09] 0.91 0.98 [0.89–1.08] 0.69
Bold values indicate level of signiﬁcance = 5%
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Therefore, a different approach is required.
Our study demonstrated impairment of cardiac autonomic, particu-
larly vagal, function in CKD patients. Further evaluation of the outcome
of CKD patients and its relationship with the autonomic circadian im-
pairment should be conducted.
This veriﬁcationmay lead to the introduction of autonomic modula-
tion therapy to decrease not only the incidence of SCD, but also the de-
teriorative consequence in renal outcomes in CKD patients [21].
Indeed, Gronda et al. have recently reported that baroreﬂex activa-
tion therapy improved clinical parameters in heart failure patients
[25]. Patients with heart failure have impaired autonomic function,
and this has been shown to be associated with poor prognosis. Thus,
the impaired cardiac autonomic activity in CKD patients, which we
have demonstrated in our study, could be a possible therapy target in
the future.
4.4. Limitations
The present study has several limitations. This was a single-center
study and a small patient cohort. The association of autonomic dysfunc-
tion and prognosis could not be analyzed, as patient follow-up was not
the end-point of our study. As previouslymentioned, it is complicated to
discuss the nature of the cardiac autonomic systemwith power spectral
analysis [13]. Future researchwithmulti-center and larger patient num-
bers should be performed to conﬁrm that autonomic dysfunction in pa-
tients with non-diabetic CKD affects prognosis. Due to the retrospective
analysis, no data on obstructive sleep apneawas available, which can af-
fect the autonomic nervous system [26]. However, we have consecu-
tively included CKD patients, therefore we believe that the data
should be reﬂective of real-world CKD patients.
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